Biomabs

Biomabs is a leading Chinese biopharmaceutical company focused on the development and industrialization of monoclonal antibody drugs. Based in Shanghai, the company operates a large-scale manufacturing base that supports the production of biosimilars and novel antibody therapies for oncology and autoimmune disorders. Biomabs has successfully brought several biosimilars to market in China, including versions of infliximab, omalizumab, and cetuximab. As a core subsidiary of the publicly traded Mabpharm Limited, Biomabs leverages its integrated R&D and GMP-certified manufacturing capabilities to provide affordable high-quality biologics. The company's pipeline continues to expand with late-stage candidates targeting HER2, RANKL, and other validated pathways.